St. Jude charges infringement by Vigor pacer, Ventak Mini ICD in letter to Guidant.
This article was originally published in The Gray Sheet
Executive SummaryST. JUDE PACER/ICD PATENT CROSS-LICENSE WITH GUIDANT sought by St. Jude's Pacesetter business, Guidant says in a Sept. 6 supplement to its offering circular-prospectus for its split-off from Lilly. In an Aug. 28 letter, according to Guidant, Pacesetter says it believes Guidant's Cardiac Pacemakers, Inc. unit is using certain Pacesetter patents in its Vigor pacemaker/programmer combination and that it "may also be using two patents licensed to Pacesetter" in its Ventak Mini automatic implantable cardioverter defibrillator.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.